To find more information on UCLH Early Phase Cancer Clinical Trials, including eligibility criteria, click the hyperlinked Local Project Reference (LRP) ID, which will take you to the UCLH Find a Study database.
Additional early phase clinical trials recruiting Lung cohorts may be found in the Advanced Solid Tumour Trials Portfolio page.
APL-101-01Safety and efficacy of APL-101 in NSCLC and advanced solid tumors: Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors | |
---|---|
Local Project Reference: | 129619 |
Principal Investigator: | Dr. Martin Forster |
Drug Class/ Treatment: | APL-101 (C-Met Inhibitor) |
Patient Population: | Non-Small Cell Lung Cancer (NSCLC) |
Trial Hosted By - UCLH Clinical Research Facility (CRF) |
FURMO 002A PHASE 1b DOSE ESCALATION AND DOSE EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF FURMONERTINIB IN PATIENTS WITH ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH ACTIVATING EGFR OR HER2 MUTATIONS, INCLUDING EXON 20 INSERTION MUTATIONS | |
---|---|
Local Project Reference: | 150619 |
Principal Investigator: | Dr Martin Forster |
Drug Class/Treatment: | Furmonertinib (EGFR Tyrosine-Kinase Inhibitor) |
Patient Population: | Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 Mutations (Including Exon 20 Insertion Mutations) |
Trial Hosted By - UCLH Clinical Research Facility (CRF) |
ATX-NS-001 (CHIRON)ATX-NS-001 - ATL001 for the Treatment of Non-Small Cell Lung Cancer: An open label, multi-centre, phase I/IIa study evaluating the safety and clinical activity of neo-antigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON) | |
---|---|
Local Project Reference: | 18/0540 |
Principal Investigator: | Dr. Martin Forster |
Drug Class/ Treatment: | ATL001 - Autologous Clonal Neoantigen Reactive T-Cell (cNeT) |
Patient Population: | Non-Small Cell Lung Cancer (NSCLC) |
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) |
PALOMA-2A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer | |
---|---|
Local Project Reference: | 1006215 |
Principal Investigator: | Dr Sarah Benafif |
Drug Class/ Treatment: | Amivantamab (Bi-specific EGF & MET Receptor-Directed Antibody) Subcutaneous |
Patient Population: | Non-Small Cell Lung Cancer (NSCLC):
|
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) |
CONCORDEA platform study of DNA damage response inhibitors in combination with conventional radiotherapy in non small cell lung cancer | |
---|---|
Local Project Reference: | 118073 |
Principal Investigator: | Dr. Crispin Hiley |
Drug Class/ Treatment: | Radiotherapy + Olaparib (PARP Inhibitor) or AZD1390 (Oral ATM Inhibitor) |
Patient Population: | Non-Small Cell Lung Cancer |
Trial Hosted By - UCLH Cancer Clinical Trials Unit (CCTU) |
METalmark (Kaleidoscope) A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer | |
---|---|
Local Project Reference: | 152527 |
Principal Investigator: | Dr Sarah Benafif |
Drug Class/ Treatment: | Amivantamab (Bi-Specific Antibody) + Capmatinib (C-Met RTK)Phase II Dose Expansion |
Patient Population: | Non-Small Cell Lung Cancer (NSCLC)
|
Trial Hosted By - UCLH Clinical Research Facility (CRF) |